While pivotal research on therapies for neovascular age-related macular degeneration (nAMD) and geographic atrophy (GA) focused on one condition or the other, retina specialists commonly encounter ...
Ocugen (NASDAQ:OCGN) outlined plans to advance three late-stage retinal disease programs, with company speaker Shankar saying ...
For decades, treatments for macular degeneration have focused on slowing, not restoring vision loss. A new retinal implant is flipping that script, turning patients with geographic atrophy into ...
Astellas Pharma US, Inc. (Head of US Commercial: Michael Petroutsas, "Astellas") today announced new research insights at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting, ...
The examination and diagnosis of geographic atrophy (GA) is done by combining ophthalmological and imaging techniques. The first step in diagnosing age-related macular degeneration (AMD), including GA ...
Ocugen, Inc. announced that the Data and Safety Monitoring Board has approved the continuation of the second phase of the Phase 1/2 OCU410 ArMaDa clinical trial for treating geographic atrophy (GA) ...
Distinct retinal vessel atrophy patterns may be associated with multiple sclerosis (MS), but further research is needed to assess retinal vessel changes and their underlying role in MS. Changes in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results